Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study

Darla K. Liles; Nirmish R. Shah; Brigid Scullin; Victor R. Gordeuk; Wally R. Smith; Julie Kanter; Maureen M. Achebe; Ralph Boccia; Shelley E. Crary; Walter K. Kraft; Natasha Archer; Vince Cataldo; Brandon M. Hardesty; Modupe Idowu; Payal C. Desai; Alan Ikeda; Geetha Puthenveetil; Kathryn L. Hassell; Sharada Sarnaik; Abdullah Kutlar

doi:10.1111/bjh.17739

Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study

Darla K. Liles, Nirmish R. Shah, Brigid Scullin, Victor R. Gordeuk, Wally R. Smith, Julie Kanter, Maureen M. Achebe, Ralph Boccia, Shelley E. Crary, Walter K. Kraft, Natasha Archer, Vince Cataldo, Brandon M. Hardesty, Modupe Idowu, Payal C. Desai, Alan Ikeda, Geetha Puthenveetil, Kathryn L. Hassell, Sharada Sarnaik, Abdullah Kutlar

Pulmonary Disease

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	e150-e153
Journal	British Journal of Haematology
Volume	195
Issue number	4
DOIs	https://doi.org/10.1111/bjh.17739
State	Published - Nov 2021

Keywords

crizanlizumab
monoclonal antibody
sickle cell disease
vaso-occlusive crisis

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.17739

Cite this

Liles, D. K., Shah, N. R., Scullin, B., Gordeuk, V. R., Smith, W. R., Kanter, J., Achebe, M. M., Boccia, R., Crary, S. E., Kraft, W. K., Archer, N., Cataldo, V., Hardesty, B. M., Idowu, M., Desai, P. C., Ikeda, A., Puthenveetil, G., Hassell, K. L., Sarnaik, S., & Kutlar, A. (2021). Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. British Journal of Haematology, 195(4), e150-e153. https://doi.org/10.1111/bjh.17739

Liles, DK, Shah, NR, Scullin, B, Gordeuk, VR, Smith, WR, Kanter, J, Achebe, MM, Boccia, R, Crary, SE, Kraft, WK, Archer, N, Cataldo, V, Hardesty, BM, Idowu, M, Desai, PC, Ikeda, A, Puthenveetil, G, Hassell, KL, Sarnaik, S & Kutlar, A 2021, 'Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study', British Journal of Haematology, vol. 195, no. 4, pp. e150-e153. https://doi.org/10.1111/bjh.17739

@article{c35c71738eb24d6eb56ee9c368aa3ec2,

title = "Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study",

keywords = "crizanlizumab, monoclonal antibody, sickle cell disease, vaso-occlusive crisis",

author = "Liles, {Darla K.} and Shah, {Nirmish R.} and Brigid Scullin and Gordeuk, {Victor R.} and Smith, {Wally R.} and Julie Kanter and Achebe, {Maureen M.} and Ralph Boccia and Crary, {Shelley E.} and Kraft, {Walter K.} and Natasha Archer and Vince Cataldo and Hardesty, {Brandon M.} and Modupe Idowu and Desai, {Payal C.} and Alan Ikeda and Geetha Puthenveetil and Hassell, {Kathryn L.} and Sharada Sarnaik and Abdullah Kutlar",

note = "Funding Information: Darla K. Liles has no conflicts to disclose. Nirmish R. Shah, reports consultancy fees and research funding from Novartis Pharmaceuticals Corporation and Global Blood Therapeutics; consultancy fees at CSL Behring and bluebird bio; speaker{\textquoteright}s bureau participation at Global Blood Therapeutics and Novartis Pharmaceuticals Corporation, outside of the submitted work. Brigid Scullin, reports honoraria from PHAR, LLC, and Novartis Pharmaceuticals Corporation, outside of the submitted work. Victor R. Gordeuk, reports grant support from Novartis Pharmaceuticals Corporation during conduct of the study; grant support from Global Blood Therapeutics, Imara, Inc., Takeda, Ironwood, Incyte, CSL Behring, and Pfizer; consultancy fees from CSL Behring, Forma Therapeutics, and Novartis Pharmaceuticals Corporation, outside of the submitted work. Wally R. Smith, reports research funding from consultancy fees from National Heart Lung and Blood institute, Novartis Pharmaceuticals Corporation, Patient‐Centered Outcomes Research Institute, and the United States Department of Health and Human Services/Health Resources and Services Administration, Pfizer Inc., Novartis Pharmaceuticals Corporation, Emmaus Medical, Inc., Imara Inc., and Shire; consultancy fees from Global Blood Therapeutics, Emmaus Medical, Inc., Pfizer Inc., and Novartis Pharmaceuticals Corporation, outside of the submitted work. Julie Kanter, reports funding from Novartis Pharmaceuticals Corporation during the conduct of the study, and honoraria from Novartis Pharmaceuticals Corporation, outside of the submitted work. Maureen M. Achebe has no conflicts to disclose. Ralph Boccia has no conflicts to disclose. Shelley E. Crary has no conflicts to disclose. Walter K. Kraft, reports grant support from Novartis Pharmaceuticals Corporation during the conduct of the study. Natasha Archer, reports grant support from Novartis Pharmaceuticals Corporation during the conduct of the study; grant support from Global Blood Therapeutics and from the American Society of Hematology/Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Award, outside of the submitted work. Vince Cataldo has no conflicts to disclose. Brandon M. Hardesty, reports fees for research from Global Blood Therapeutics and Novartis Pharmaceuticals Corporation, outside the submitted work. Modupe Idowu, reports grant support from UT Health McGovern Medical School, Houston, Texas, outside of the submitted work. Payal C. Desai, reports grant support from Selexys during the conduct of the study. Alan Ikeda has no conflicts to disclose. Geetha Puthenveetil has no conflicts to disclose. Kathryn L. Hassell, reports fees from Selexys and Novartis Pharmaceuticals Corporation during the conduct of the study; fees from Pfizer Inc., outside of the submitted work. Sharada Sarnaik has no conflicts to disclose. Abdullah Kutlar, reports consultancy fees, during the conduct of the study, and personal fees for participation in clinical trials from Novartis Pharmaceuticals Corporation; personal fees for participation in clinical trials and speaker program from Global Blood Therapeutics; honoraria from Blueprint Research Group, Saudi Society of Blood and Marrow Transplantation, MUH Life Sciences, and Vindico Medical Education; personal fees (DSMB membership) for bluebird bio, Inc. and Micelle BioPharma, Inc., outside of the submitted work.",

year = "2021",

month = nov,

doi = "10.1111/bjh.17739",

language = "English (US)",

volume = "195",

pages = "e150--e153",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Long-term biological effects in sickle cell disease

T2 - insights from a post-crizanlizumab study

AU - Liles, Darla K.

AU - Shah, Nirmish R.

AU - Scullin, Brigid

AU - Gordeuk, Victor R.

AU - Smith, Wally R.

AU - Kanter, Julie

AU - Achebe, Maureen M.

AU - Boccia, Ralph

AU - Crary, Shelley E.

AU - Kraft, Walter K.

AU - Archer, Natasha

AU - Cataldo, Vince

AU - Hardesty, Brandon M.

AU - Idowu, Modupe

AU - Desai, Payal C.

AU - Ikeda, Alan

AU - Puthenveetil, Geetha

AU - Hassell, Kathryn L.

AU - Sarnaik, Sharada

AU - Kutlar, Abdullah

N1 - Funding Information: Darla K. Liles has no conflicts to disclose. Nirmish R. Shah, reports consultancy fees and research funding from Novartis Pharmaceuticals Corporation and Global Blood Therapeutics; consultancy fees at CSL Behring and bluebird bio; speaker’s bureau participation at Global Blood Therapeutics and Novartis Pharmaceuticals Corporation, outside of the submitted work. Brigid Scullin, reports honoraria from PHAR, LLC, and Novartis Pharmaceuticals Corporation, outside of the submitted work. Victor R. Gordeuk, reports grant support from Novartis Pharmaceuticals Corporation during conduct of the study; grant support from Global Blood Therapeutics, Imara, Inc., Takeda, Ironwood, Incyte, CSL Behring, and Pfizer; consultancy fees from CSL Behring, Forma Therapeutics, and Novartis Pharmaceuticals Corporation, outside of the submitted work. Wally R. Smith, reports research funding from consultancy fees from National Heart Lung and Blood institute, Novartis Pharmaceuticals Corporation, Patient‐Centered Outcomes Research Institute, and the United States Department of Health and Human Services/Health Resources and Services Administration, Pfizer Inc., Novartis Pharmaceuticals Corporation, Emmaus Medical, Inc., Imara Inc., and Shire; consultancy fees from Global Blood Therapeutics, Emmaus Medical, Inc., Pfizer Inc., and Novartis Pharmaceuticals Corporation, outside of the submitted work. Julie Kanter, reports funding from Novartis Pharmaceuticals Corporation during the conduct of the study, and honoraria from Novartis Pharmaceuticals Corporation, outside of the submitted work. Maureen M. Achebe has no conflicts to disclose. Ralph Boccia has no conflicts to disclose. Shelley E. Crary has no conflicts to disclose. Walter K. Kraft, reports grant support from Novartis Pharmaceuticals Corporation during the conduct of the study. Natasha Archer, reports grant support from Novartis Pharmaceuticals Corporation during the conduct of the study; grant support from Global Blood Therapeutics and from the American Society of Hematology/Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Award, outside of the submitted work. Vince Cataldo has no conflicts to disclose. Brandon M. Hardesty, reports fees for research from Global Blood Therapeutics and Novartis Pharmaceuticals Corporation, outside the submitted work. Modupe Idowu, reports grant support from UT Health McGovern Medical School, Houston, Texas, outside of the submitted work. Payal C. Desai, reports grant support from Selexys during the conduct of the study. Alan Ikeda has no conflicts to disclose. Geetha Puthenveetil has no conflicts to disclose. Kathryn L. Hassell, reports fees from Selexys and Novartis Pharmaceuticals Corporation during the conduct of the study; fees from Pfizer Inc., outside of the submitted work. Sharada Sarnaik has no conflicts to disclose. Abdullah Kutlar, reports consultancy fees, during the conduct of the study, and personal fees for participation in clinical trials from Novartis Pharmaceuticals Corporation; personal fees for participation in clinical trials and speaker program from Global Blood Therapeutics; honoraria from Blueprint Research Group, Saudi Society of Blood and Marrow Transplantation, MUH Life Sciences, and Vindico Medical Education; personal fees (DSMB membership) for bluebird bio, Inc. and Micelle BioPharma, Inc., outside of the submitted work.

PY - 2021/11

Y1 - 2021/11

KW - crizanlizumab

KW - monoclonal antibody

KW - sickle cell disease

KW - vaso-occlusive crisis

UR - http://www.scopus.com/inward/record.url?scp=85116397596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116397596&partnerID=8YFLogxK

U2 - 10.1111/bjh.17739

DO - 10.1111/bjh.17739

M3 - Letter

C2 - 34611900

AN - SCOPUS:85116397596

SN - 0007-1048

VL - 195

SP - e150-e153

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this